Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer

Takuya Fukazawa, Yutaka Maeda, Junji Matsuoka, Toshiro Ono, Katsumi Mominoki, Tomoki Yamatsuji, Kaoru Shigemitsu, Ichiro Morita, Ichiro Murakami, Hirotoshi Tanaka, Mary L. Durbin, Yoshio Naomoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pulmonary surfactant has been used as a carrier to deliver a therapeutic virus to dysfunctional lung cells that reside within an intricate lung structure. To investigate whether pulmonary surfactant enhances the efficacy of intratracheal instillation of a therapeutic virus to target KRAS mutation-bearing lung cancer in vivo, we developed a recombinant adenovirus that induces cell death only in lung cancer cells and injected the adenovirus into a mouse model of KRAS mutation-positive lung cancer intratracheally with and without surfactant. A therapeutic adenovirus that induces cell death only in lung cancer cells was constructed by combining a cancer-specific human telomerase reverse transcriptase (hTERT) promoter fused to CCAATIenhancerbinding protein alpha (CEBPa) with a modified lung-specific Clara cell-specific 10-κDa protein (CClO) promoter fused to cytotoxic adenovirus type 5 early region 1A (E1A). CEBPa is induced only in cancer cells and activates the CC10 promoter, which in turn induces cytotoxic E1A, and causes cell death only in lung cancer cells in vitro. This adenovirus was intratracheally administered to the model mice (CCSP-rtTA/Tet-op-K-Ras4bG12D bitransgenic mice) in the presence and absence of pulmonary surfactant. Intratracheally administered therapeutic adenovirus with pulmonary surfactant spread to airways, as well as to the alveolar region of the lung, and caused a reduction of lung tumors developed. The therapeutic adenovirus without pulmonary surfactant spread only to airways and was tenfold less effective in tumor reduction. Here, we demonstrate that pulmonary surfactant is an efficient tool to intratracheally deliver a therapeutic virus to treat KRAS mutation-positive lung cancer in vivo.

Original languageEnglish
Pages (from-to)4925-4936
Number of pages12
JournalAnticancer Research
Volume30
Issue number12
Publication statusPublished - Dec 2010

Fingerprint

Pulmonary Surfactants
Adenoviridae
Lung Neoplasms
Mutation
Genes
Lung
Cell Death
Viruses
Neoplasms
Therapeutics
Proteins
Surface-Active Agents
Cause of Death

Keywords

  • CC10
  • Gene transfer
  • Intratracheal instillation
  • Kras mutation
  • Lung cancer
  • Pulmonary surfactant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer. / Fukazawa, Takuya; Maeda, Yutaka; Matsuoka, Junji; Ono, Toshiro; Mominoki, Katsumi; Yamatsuji, Tomoki; Shigemitsu, Kaoru; Morita, Ichiro; Murakami, Ichiro; Tanaka, Hirotoshi; Durbin, Mary L.; Naomoto, Yoshio.

In: Anticancer Research, Vol. 30, No. 12, 12.2010, p. 4925-4936.

Research output: Contribution to journalArticle

Fukazawa, T, Maeda, Y, Matsuoka, J, Ono, T, Mominoki, K, Yamatsuji, T, Shigemitsu, K, Morita, I, Murakami, I, Tanaka, H, Durbin, ML & Naomoto, Y 2010, 'Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer', Anticancer Research, vol. 30, no. 12, pp. 4925-4936.
Fukazawa, Takuya ; Maeda, Yutaka ; Matsuoka, Junji ; Ono, Toshiro ; Mominoki, Katsumi ; Yamatsuji, Tomoki ; Shigemitsu, Kaoru ; Morita, Ichiro ; Murakami, Ichiro ; Tanaka, Hirotoshi ; Durbin, Mary L. ; Naomoto, Yoshio. / Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer. In: Anticancer Research. 2010 ; Vol. 30, No. 12. pp. 4925-4936.
@article{fe8bf612d5774d90b77ff20b36e13673,
title = "Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer",
abstract = "Pulmonary surfactant has been used as a carrier to deliver a therapeutic virus to dysfunctional lung cells that reside within an intricate lung structure. To investigate whether pulmonary surfactant enhances the efficacy of intratracheal instillation of a therapeutic virus to target KRAS mutation-bearing lung cancer in vivo, we developed a recombinant adenovirus that induces cell death only in lung cancer cells and injected the adenovirus into a mouse model of KRAS mutation-positive lung cancer intratracheally with and without surfactant. A therapeutic adenovirus that induces cell death only in lung cancer cells was constructed by combining a cancer-specific human telomerase reverse transcriptase (hTERT) promoter fused to CCAATIenhancerbinding protein alpha (CEBPa) with a modified lung-specific Clara cell-specific 10-κDa protein (CClO) promoter fused to cytotoxic adenovirus type 5 early region 1A (E1A). CEBPa is induced only in cancer cells and activates the CC10 promoter, which in turn induces cytotoxic E1A, and causes cell death only in lung cancer cells in vitro. This adenovirus was intratracheally administered to the model mice (CCSP-rtTA/Tet-op-K-Ras4bG12D bitransgenic mice) in the presence and absence of pulmonary surfactant. Intratracheally administered therapeutic adenovirus with pulmonary surfactant spread to airways, as well as to the alveolar region of the lung, and caused a reduction of lung tumors developed. The therapeutic adenovirus without pulmonary surfactant spread only to airways and was tenfold less effective in tumor reduction. Here, we demonstrate that pulmonary surfactant is an efficient tool to intratracheally deliver a therapeutic virus to treat KRAS mutation-positive lung cancer in vivo.",
keywords = "CC10, Gene transfer, Intratracheal instillation, Kras mutation, Lung cancer, Pulmonary surfactant",
author = "Takuya Fukazawa and Yutaka Maeda and Junji Matsuoka and Toshiro Ono and Katsumi Mominoki and Tomoki Yamatsuji and Kaoru Shigemitsu and Ichiro Morita and Ichiro Murakami and Hirotoshi Tanaka and Durbin, {Mary L.} and Yoshio Naomoto",
year = "2010",
month = "12",
language = "English",
volume = "30",
pages = "4925--4936",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer

AU - Fukazawa, Takuya

AU - Maeda, Yutaka

AU - Matsuoka, Junji

AU - Ono, Toshiro

AU - Mominoki, Katsumi

AU - Yamatsuji, Tomoki

AU - Shigemitsu, Kaoru

AU - Morita, Ichiro

AU - Murakami, Ichiro

AU - Tanaka, Hirotoshi

AU - Durbin, Mary L.

AU - Naomoto, Yoshio

PY - 2010/12

Y1 - 2010/12

N2 - Pulmonary surfactant has been used as a carrier to deliver a therapeutic virus to dysfunctional lung cells that reside within an intricate lung structure. To investigate whether pulmonary surfactant enhances the efficacy of intratracheal instillation of a therapeutic virus to target KRAS mutation-bearing lung cancer in vivo, we developed a recombinant adenovirus that induces cell death only in lung cancer cells and injected the adenovirus into a mouse model of KRAS mutation-positive lung cancer intratracheally with and without surfactant. A therapeutic adenovirus that induces cell death only in lung cancer cells was constructed by combining a cancer-specific human telomerase reverse transcriptase (hTERT) promoter fused to CCAATIenhancerbinding protein alpha (CEBPa) with a modified lung-specific Clara cell-specific 10-κDa protein (CClO) promoter fused to cytotoxic adenovirus type 5 early region 1A (E1A). CEBPa is induced only in cancer cells and activates the CC10 promoter, which in turn induces cytotoxic E1A, and causes cell death only in lung cancer cells in vitro. This adenovirus was intratracheally administered to the model mice (CCSP-rtTA/Tet-op-K-Ras4bG12D bitransgenic mice) in the presence and absence of pulmonary surfactant. Intratracheally administered therapeutic adenovirus with pulmonary surfactant spread to airways, as well as to the alveolar region of the lung, and caused a reduction of lung tumors developed. The therapeutic adenovirus without pulmonary surfactant spread only to airways and was tenfold less effective in tumor reduction. Here, we demonstrate that pulmonary surfactant is an efficient tool to intratracheally deliver a therapeutic virus to treat KRAS mutation-positive lung cancer in vivo.

AB - Pulmonary surfactant has been used as a carrier to deliver a therapeutic virus to dysfunctional lung cells that reside within an intricate lung structure. To investigate whether pulmonary surfactant enhances the efficacy of intratracheal instillation of a therapeutic virus to target KRAS mutation-bearing lung cancer in vivo, we developed a recombinant adenovirus that induces cell death only in lung cancer cells and injected the adenovirus into a mouse model of KRAS mutation-positive lung cancer intratracheally with and without surfactant. A therapeutic adenovirus that induces cell death only in lung cancer cells was constructed by combining a cancer-specific human telomerase reverse transcriptase (hTERT) promoter fused to CCAATIenhancerbinding protein alpha (CEBPa) with a modified lung-specific Clara cell-specific 10-κDa protein (CClO) promoter fused to cytotoxic adenovirus type 5 early region 1A (E1A). CEBPa is induced only in cancer cells and activates the CC10 promoter, which in turn induces cytotoxic E1A, and causes cell death only in lung cancer cells in vitro. This adenovirus was intratracheally administered to the model mice (CCSP-rtTA/Tet-op-K-Ras4bG12D bitransgenic mice) in the presence and absence of pulmonary surfactant. Intratracheally administered therapeutic adenovirus with pulmonary surfactant spread to airways, as well as to the alveolar region of the lung, and caused a reduction of lung tumors developed. The therapeutic adenovirus without pulmonary surfactant spread only to airways and was tenfold less effective in tumor reduction. Here, we demonstrate that pulmonary surfactant is an efficient tool to intratracheally deliver a therapeutic virus to treat KRAS mutation-positive lung cancer in vivo.

KW - CC10

KW - Gene transfer

KW - Intratracheal instillation

KW - Kras mutation

KW - Lung cancer

KW - Pulmonary surfactant

UR - http://www.scopus.com/inward/record.url?scp=78751475672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751475672&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 4925

EP - 4936

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -